EP2874604A1 - Use of an amphoteric chelating agent for preventing contact allergies - Google Patents

Use of an amphoteric chelating agent for preventing contact allergies

Info

Publication number
EP2874604A1
EP2874604A1 EP13747452.4A EP13747452A EP2874604A1 EP 2874604 A1 EP2874604 A1 EP 2874604A1 EP 13747452 A EP13747452 A EP 13747452A EP 2874604 A1 EP2874604 A1 EP 2874604A1
Authority
EP
European Patent Office
Prior art keywords
chelating agent
contact
allergies
representing
ethylene diamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP13747452.4A
Other languages
German (de)
French (fr)
Other versions
EP2874604B1 (en
Inventor
Joël Blomet
Laurence Mathieu
Marie-Claude Meyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prevor International SARL
Original Assignee
Prevor International SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prevor International SARL filed Critical Prevor International SARL
Priority to PL13747452T priority Critical patent/PL2874604T3/en
Publication of EP2874604A1 publication Critical patent/EP2874604A1/en
Application granted granted Critical
Publication of EP2874604B1 publication Critical patent/EP2874604B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/51—Chelating agents

Definitions

  • the present invention relates to the field of products for preventing contact allergies.
  • Natural rubber or latex is an aqueous emulsion of spherical polyisoprene droplets wrapped in a layer of water soluble proteins. It can be of synthetic or natural origin. In natural form it comes from the sap of Hevea brasiliensis. He is very present in the objects of everyday life. Examples of objects made of latex or comprising latex which are therefore likely to cause allergic reactions include household gloves, tires, balloons, teats, diving tubes, fins, swimming goggles, swim caps, glues, grips tennis racket grips, condoms, medical equipment: elastic bandages, syringes with rubber gaskets, probes, pads, infusion sets, dental gutters and gloves exams or surgeons, etc.
  • the present invention relates to the use of at least one amphoteric chelating agent which comprises a complex based on aluminum and ethylene diamine tetraacetic acid or its trisodium salt having the general formula [Al (Y ) B n] c 'c D with B representing OH ⁇ , ⁇ B0 2, H +, Y representing a tetracarboxylate can be protonated four times to form the ethylene diamine tetraacetic acid, n is an integer equal to 0, 1, 2 or 3, D being a counter-ion, preferably Na + , c being an integer of 0, 1, 2 or 3 and c 'being a relative number having the same absolute value as c, to prevent allergies of contact.
  • the present invention relates to a device comprising a portion of allergenic material, in particular latex, intended to come into contact with the skin or the mucous membranes, which is covered by a layer containing at least one amphoteric chelating agent such as mentioned above.
  • the present invention relates to the use of a composition comprising at least said amphoteric chelating agent mentioned above and at least one excipient, to prevent contact allergies.
  • the present invention relates to the use of at least one amphoteric chelating agent which comprises a complex based on aluminum and ethylene diamine tetraacetic acid or its trisodium salt having the general formula [Al (Y) n B] c ' D c with B representing OH " , B0 2 " , H + , Y representing a tetracarboxylate which can be protonated four times to form ethylene diamine tetraacetic acid, n being an integer of 0, 1, 2 or 3, D being a counterion, preferably Na + , where c is an integer equal at 0, 1, 2 or 3 and c 'being a relative number having the same absolute value as c, to prevent contact allergies, in particular rubber allergies.
  • contact allergies means all allergies that are caused by repeated contact with the skin and / or mucous membranes of allergenic substances.
  • allergens present in objects or devices likely to come into contact with the skin and / or the mucous membranes and which cause contact allergies mention may be made of latex proteins, heavy metals such as Al, As , Cd, Cr, Hg, Ni, Pb, Sr and Te, tetramethylthiuram disulfide, 2-mercaptobenzothiazole, benzyl carbamate, bisphenol, ethyl acrylate, araldite 506 epoxy Resin, methanal, Protein-type allergens (such as profilins, tropomyosins, LTPs (lipid transfer proteins), betv 1-like PR-10 proteins, polcalcines, beta parvalbumin, 2s albumin, beta expansins , polygalacturonases, Ag5 (antigens 5), albumins, caseins, lipocalins, group 5 grass
  • the invention is particularly suitable for the prevention of allergies to rubber, and particularly to natural rubber.
  • "rubber allergies” means allergies caused by the proteins present in the natural rubber derived from the Hevea brasiliensis tree, but also by other allergenic substances present in the rubber. Examples of such allergenic proteins include hevein, prohevein, profilin, elongation factor of rubber, endo-1,3-glucosidase, and the like.
  • non-protein allergenic substances present in the rubber are vulcanizing agents (thiurams, dithiocarbamates, benzothiazoles, guanidines, and thioureas), antioxidants or antiozonants (PPD derivatives - phenylene paradiamine and quinolines), phenols ( hydroquinones), phosphites ... or other additives such as chlorhexidine digluconate, dimethyl didecyl ammonium chloride salts, isothiazolinones, formaldehyde, various metals, etc.
  • vulcanizing agents thiurams, dithiocarbamates, benzothiazoles, guanidines, and thioureas
  • antioxidants or antiozonants PPD derivatives - phenylene paradiamine and quinolines
  • phenols hydroquinones
  • phosphites ... or other additives such as chlorhexidine digluconate, dimethyl didecyl ammonium chloride salts, is
  • Such contact allergies are manifest as contact dermatitis, contact urticaria, eczema, rhinitis, conjunctivitis, asthma, anaphylactic shock.
  • amphoteric chelating agent of general formula [Al (Y) n B] c 'c D used according to the invention can be preferably formed by a substantially stoichiometric combination of aluminum ion Al 3+, Y ligand and a stabilizing agent chosen from OH ⁇ , B02 ⁇ or H + .
  • a stabilizing agent chosen from OH ⁇ , B02 ⁇ or H + chosen from OH ⁇ , B02 ⁇ or H + .
  • said complex based on aluminum and Y is stabilized by a weak base such that the amino acids chosen from the group comprising glycine, histidine, arginine, lysine, phenylalanine alanine, isoleucine, leucine, methionine, proline, valine, tryptophan, serine, glutamine, cystine and mixtures thereof.
  • Glycine is quite appropriate.
  • amphoteric chelating agent is carried out so that it is in contact with the skin and / or the mucous membranes.
  • Langerhans cells are dendritic cells that are found in the epidermis and contain Birbeck granules. They normally exist in lymph nodes and in the skin in the stratum spinosum of the epidermis. These cells specialized in the capture of antigens are activated when the skin is put in contact with an allergen. This presents a first sign of the beginning of an awareness process. Immunolabelling methods, in particular CDla surface receptors of Langerhans cells make it possible to measure their number and to observe their migration from the epidermis to the dermis.
  • the preventive composition of the invention is effective if the antigen is stopped, that is to say not captured by epidermal Langerhans cells. These will not migrate to the dermis.
  • the effectiveness of the composition according to the invention is therefore measured by the number of non-migrating Langerhans cells per centimeter of epidermis. No significant migration of the number of these cells has been observed after contacting the skin zone covered by the composition. according to the invention with allergenic agents and in particular with the allergenic proteins of natural rubber such as hevein.
  • the invention also relates to a device comprising a portion of material capable of containing allergens for contact with the skin or the mucous membranes, which is covered by a layer containing at least one amphoteric chelating agent which comprises a d-based complex.
  • aluminum and ethylene diamine tetraacetic acid or its trisodium salt having the general formula [Al (Y) B n ] c D c with B representing OH " , B0 2 " , H + , Y being a tetracarboxylate which may be protonated four times to form ethylene diamine tetraacetic acid, where n is an integer of 0, 1, 2 or 3, D being a counterion, preferably Na + , where c is an integer of 0, 1, 2 or 3 and c 'being a relative number having the same absolute value as c.
  • the invention is particularly suitable for rubber devices or having a rubber part intended to come into contact with the skin and / or the mucous membranes.
  • Examples of devices according to the invention are condoms, gloves, finger cots, dressings and compresses, medical devices such as probes, tubing, drainage devices, infusion devices, medical devices useful in urology, medical devices of the invention. first respiratory, etc.
  • At least the part of the device intended to come into contact with the skin and / or the mucous membranes is covered with a film comprising said amphoteric chelating agent.
  • Said film is preferably a lubricating preparation.
  • both the outer surface and the inner surface may be coated with a lubricating preparation comprising said amphoteric chelating agent so as to prevent both partners from experiencing latex allergies.
  • the invention also relates to the use of a composition
  • a composition comprising at least one amphoteric chelating agent which comprises a complex based on aluminum and ethylene diamine tetraacetic acid or its trisodium salt having the general formula [Al (Y) B n ] c ' D c with B representing OH ⁇ , ⁇ 2 ⁇ , H + , Y representing a tetracarboxylate that can be protonated four times to form ethylene diamine tetraacetic acid, n representing an integer equal to 0, 1, 2 or 3, D being a counterion, preferably Na + , where c is an integer equal to 0, 1, 2 or 3 and c 'is a relative number having the same absolute value as c, and at least one excipient, for prevent contact allergies and especially rubber allergies.
  • composition may be in the form of an oil-in-water or water-in-oil emulsion, in the form of a gel, in particular a hydrophilic gel or a silicone gel.
  • Said excipient present in the composition is an excipient of pharmaceutical or cosmetic quality.
  • excipients that may be present in the composition according to the invention are chosen from a gelling agent, surfactants, synthetic or natural waxes or oils, moisturizing and emollient agents, antiperspirants, additives improving texture such as conditioners and thickeners, preservatives, cosmetic and food colorants, fragrances, flavorings, pH control agents and mixtures thereof.
  • the gelling agent or thickener may be hydrophilic or may be of the silicone type.
  • the hydrophilic gelling agents may be synthetic, semi-synthetic or natural gelling agents of plant, microbial, animal or mineral origin.
  • Hydrophilic gelling agents may be, for example, polymers and copolymers of acrylic acid, crosslinked polymers, C 10-30 alkyl acrylate, polyacrylamide, poloxamer, cellulose derivatives (esters and ethers), silicas, fumed silica, silicates , such as magnesium-aluminum silicates, chitin and its derivatives, gelatin, xanthan, dextran, gellan, carrageenans, alginates, agar-agar, agar, pectin, acacia gum, karaya gum, gum tragacanth, gum arabic, gum guar, locust bean gum, starch and its derivatives, scleroglucan.
  • concentration of gelling agent or thickener is from 0.01 to 10% by weight, preferably from 0.1 to 5% by weight, and more preferably from 0.5 to 3% by weight of the total weight of the composition.
  • the silicone-type gelling agent is, for example, a polysiloxane-s-.
  • the surfactant may be hydrophobic with a HLB of 3 to 10 or hydrophilic with an HLB of 11 to 18.
  • This surfactant is selected from the group consisting of ethoxylated fatty alcohols, fatty acids and esters (eg Example: ceteart-12, ceteart-20, ceteareth-33, stearyl cetyl alcohol 20-ethoxylated, 2-polyhydroxystearate polyglyceryl, glyceryl oleate, sorbitan ester, glycerol ester, PEG-mono / di-laurate, PEG-mono / di stearate, cetearyl isononanoate, glyceryl stearate, etc.), carboxylates, ethoxycarboxylates (for example: sodium / potassium stearate, alkyl carboxylic acid, carboxylic acid alkyl polyglycol ether, carboxylic acid ether polyglycol alkyl phenol, carboxy
  • Waxes or synthetic or natural oils selected from the group comprising carnauba extract, beeswax, shea butter, triglycerides, stearines, fatty acid esters (for example: cetearyl alcohols, cetyl palmitate dicapryl ethers, dicaprylic carbonates, cetearyl isononanates, distearyl-tricarbonate dimers, etc.), silicone oils, zinc stearates, polyisobutenes, octyldodecanol, octyldecylxylosides, fatty alcohols, fatty acids (eg lauric acid) , myristic acid, stearic acid, etc.), vegetable oils (for example: sunflower, jojoba, coconut nucifera, soya, almond, etc.), petroleum jelly, lanolin, and mixtures thereof.
  • fatty acid esters for example: cetearyl alcohols, cetyl palmitate dicapryl ethers, dicaprylic carbon
  • the moisturizing and emollient agents may be chosen from the group comprising allantoin, polyol (for example glycerol, glycerol polymers, propylene glycol, sorbitol, etc.), plant extracts (for example extracts of aloe vera, chamomile, cucumber). calendula, etc.), hyaluronic acid, pyrrolidone carboxylic acid, urea, chitosan, tocopherol, panthenol, butylene glycol, phospholipid, linoleic acid, ⁇ -linoleic acid, alpha-bisabolol, and mixtures thereof.
  • polyol for example glycerol, glycerol polymers, propylene glycol, sorbitol, etc.
  • plant extracts for example extracts of aloe vera, chamomile, cucumber). calendula, etc.
  • hyaluronic acid for example extracts of aloe ver
  • the concentration of moisturizing and emollient agents is from 0.1 to 20% by weight, preferably from 0.5 to 10% by weight, and more preferably from 1 to 5% by weight of the total weight of the composition.
  • the antiperspirants may be selected from the group consisting of aluminum salts, preferably the sesqui-aluminum hydrochloride, aluminum and zirconium salts, complexes of aluminum-zirconium octachlorohydrex glycine and mixtures thereof.
  • concentration of antiperspirant agent is 0.1 to 50% by weight, preferably 10 to 30% by weight, and more preferably 15% by weight of the total weight of the composition.
  • Conditioners may be selected from the group consisting of polycationic polymers designated according to the INCI polyquaternium nomenclature, quaternized gums, quaternized phospholipids, and mixtures thereof.
  • the conditioner concentration is from 0.1 to 20% by weight, preferably from 0.5 to 10% by weight, and more preferably from 0.5 to 5% by weight of the total weight of the composition.
  • the preserving agents may be chosen from the group comprising: para-hydroxybenzoic alkyl ester, isothiazolinone, imidazolidinyl urea, diazolidinyl urea, bromo-nitro-propanediol, phenoxyethanol, sorbic acid and its salts, benzoic acid and its salts, phenoxyethanol, benzyl alcohol, and mixtures thereof.
  • the concentration is the one authorized in cosmetics.
  • the concentration of cosmetic and food colorants, perfumes, flavorings, pH-regulating agents eg citric acid, lactic acid, phosphoric acid, sodium hydroxide, potassium hydroxide, amino-methylpropanol, triethanolamine, etc.
  • concentration of cosmetic and food colorants, perfumes, flavorings, pH-regulating agents eg citric acid, lactic acid, phosphoric acid, sodium hydroxide, potassium hydroxide, amino-methylpropanol, triethanolamine, etc.
  • pH-regulating agents eg citric acid, lactic acid, phosphoric acid, sodium hydroxide, potassium hydroxide, amino-methylpropanol, triethanolamine, etc.
  • the composition is a gelling preparation, in particular a lubricating preparation.
  • the lubricating preparation is a hydrophilic preparation, a silicone preparation or a vaseline lubricating preparation containing said amphoteric chelating agent or in liquid form or in solid form.
  • the amount of amphoteric chelating agent present in said composition is from 0.01 to 5%, preferably from 0.02 to 4.4% and more preferably from approximately 2% by weight of the total weight of the composition.
  • the amounts of allergens are very low, especially when using deproteinized latex, very small amounts, even less than 0.01%, could be sufficient. However, in most cases less than 0.01% does not provide a sufficient preventive effect. Beyond 5%, no noticeable improvement is observed.
  • the composition is used for topical application, more particularly cutaneous. It can also be used by application on the surface of the device intended to come into contact with the skin and / or the mucous membranes.
  • the present inventors are of the opinion that the composition according to the invention makes it possible to provide a physical and chemical barrier against allergens. More particularly, after application and drying, a barrier layer covers the skin thus ensuring a physical barrier between the skin and the external environment, the amphoteric chelating agent ensuring a chemical barrier by chelating or chemically reacting with the incoming allergens. in contact with this composition.
  • the composition must completely cover the area of skin and / or mucosa that may come into contact with the latex device, typically hands for latex gloves or sex for condoms. It must be applied over the entire contact area.
  • the amount of application of the composition according to the invention is in the proportion of approximately 0.5 to 5 mg / cm 2 , preferably of approximately 1 to 3 mg / cm 2 , and still more preferably of approximately 1, 5 mg / cm 2.
  • amphoteric chelating agent used has the following formula: [A1YB02] 2-
  • the gel is prepared as follows: the water is poured into a container. It is stirred while adding the gum and the amphoteric chelating agent. Let stand 10 min.
  • Brookfield viscosity 18000 cP measured at a temperature of 20 (+/- 1) ° C and with a mobile speed at 3/20 rpm
  • BEM medium BIO-EC Explant Medium
  • Example 3 The composition of Example 3 is tested against the following allergens:
  • Heavy metals Al, As, Cd, Cr, Hg, Ni, Pb, Sr, Te
  • V Ref 0C467028 Merck
  • Araldite 506 Epoxy Resin - A3183;
  • a TB is applied the composition of Example 3 above on the skin explants at a dosage of 3 mg / cm 2. It is allowed to dry for 15 minutes.
  • 25 ⁇ l of a solution of one of the allergens chosen from the above list are applied to the skin explants protected by the emulsion of Example 3 (test) and are also applied to non-skin explants. -protected (witness). It is left to rest until T 4h , which represents 4 hours of exposure to the allergen without washing or abrasive friction.
  • emulsion-protected explants are prepared in the same way but are not brought into contact with a test substance (control).
  • the protective efficacy against allergens is measured by the immunostain analysis of CDla.
  • the paraffin sections of Langerhans cells are immunostained with anti-CDla monoclonal antibodies (ref IM1590, clone O10, Beckman Coulter) for 1 hour at ambient temperature. This immunostaining is enhanced by a streptavidin / biotin system (Vector, PK-7200) and revealed using VIP (Vector, SK-4600).
  • the nuclei are counterstained by Masson hemalum. Langerhans cells are counted on each section along the epidermis. The length of each section is measured by the Olympus Cell software and the average number of Langerhans cells per centimeter of epidermis is calculated.
  • the effectiveness of protection against the allergen is measured by the number of Langerhans cells that have not migrated.
  • Figure 1 shows the explants at T 0 and Figure 2 at T 4h for hevein.
  • the stratum corneum is thin, compact and moderately filled with keratin on the surface and remarkably below.
  • the epidermis has 4-5 cell layers with good morphology and mild spongiosis on stratum germinativum.
  • the junction relief between the dermis and the epidermis is marked.
  • the papillary dermis has fairly thick fibers that build a dense network and is well cellularized without any apparent histological lysis zone.
  • the epidermis of unprotected explants presents 4-5 cell layers with remarkable morphological changes. These changes are characterized by marked cytoplasmic denaturation (protein alteration), marked pycnosis and marked spongiosis on stratum germinativum.
  • Example 3 protects the skin effectively against hevein.
  • lubricant comprising:
  • This gel is applied by coating on the inner and outer sides of a natural rubber preservative in an amount of 2.0 +/- 0.5 mg / cm 2 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Detergent Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to the use of at least one amphoteric chelating agent which comprises a complex based on aluminium and on ethylenediaminetetraacetic acid or the trisodium salt thereof, having the general formula [Al(Y)Bn]c'Dc with B being OH-, BO2 - or H+,Y being a tetracarboxylate which can be protonated four times to form ethylenediaminetetraacetic acid, n being an integer equal to 0, 1, 2 or 3, D being a counterion, preferably Na+, c being an integer equal to 0, 1, 2 or 3 and c' being a relative number having the same absolute value as c, for preventing contact allergies. It also relates to a device, a part of which comprises said amphoteric chelating agent.

Description

UTILISATION D'UN AGENT CHELATANT AMPHOTERE POUR USE OF AMPHOTERE CHELATING AGENT FOR
PREVENIR LES ALLERGIES DE CONTACT PREVENTING ALLERGIES OF CONTACT
Domaine de l' invention  Field of the invention
La présente invention se rapporte au domaine des produits de prévention des allergies de contact.  The present invention relates to the field of products for preventing contact allergies.
Contexte de l' invention  Context of the invention
Les allergies de contact, et notamment l'allergie due au contact avec des objets ou dispositifs en caoutchouc ont fortement augmenté ces dernières années. Bien qu'habituellement modérés, les symptômes peuvent dans certains cas avoir de lourdes conséquences. Les allergies peuvent en effet être de deux types :  Contact allergies, including allergy due to contact with rubber objects or devices, have increased significantly in recent years. Although usually mild, the symptoms can in some cases have serious consequences. Allergies can indeed be of two types:
-immédiate avec urticaire, rhinite, conjonctivite, asthme et risque d' anaphylaxie (état de choc et /ou asphyxie ;  - Immediate with urticaria, rhinitis, conjunctivitis, asthma and risk of anaphylaxis (shock and / or asphyxia;
- retardée avec dermite de contact allergique (eczéma) .  - delayed with allergic contact dermatitis (eczema).
Les allergies de contact se développent par la répétition du contact avec des substances allergènes.  Contact allergies develop through repetition of contact with allergenic substances.
L'allergie au caoutchouc, et en particulier au latex, plus particulièrement au latex naturel, touche 1 à 5 % de la population. Elle touche plus particulièrement les personnes exposées à des contacts répétés au caoutchouc, comme les personnes travaillant dans l'univers médical. Ainsi, 5 % à 22 % du personnel médical, infirmières, médecins, chirurgiens, kinésithérapeutes, podologues, développent des allergies au caoutchouc. Les malades qui ont subi de nombreuses opérations sont également susceptibles de développer des allergies au latex, tout comme les personnels des laboratoires, des salons de coiffure qui utilisent des gants en caoutchouc, les personnes qui utilisent les méthodes prophylactiques des préservatifs et les personnels de l'industrie du caoutchouc . L'allergie au caoutchouc représente la 2e cause de choc anaphylactique au cours d'une anesthésie. L'allergie au caoutchouc naturel (LN) a été reconnue comme un problème de santé publique depuis la fin des années 1980. Allergy to rubber, especially latex, especially natural latex, affects 1 to 5% of the population. It particularly affects people exposed to repeated contact with rubber, such as people working in the medical world. Thus, 5% to 22% of the medical staff, nurses, doctors, surgeons, physiotherapists, chiropodists, develop allergies to rubber. Patients who have undergone many operations are also likely to develop latex allergies, as do laboratory staff, hair salons that use rubber gloves, people who use condom prophylaxis, and people who use latex. rubber industry. Rubber allergy is the second leading cause of anaphylactic shock during anesthesia. Natural rubber allergy (LN) has been recognized as a public health problem since the late 1980s.
Le caoutchouc naturel ou latex est une émulsion aqueuse de gouttelettes sphériques de polyisoprène enveloppées d'une couche de protéines hydrosolubles . Il peut être d'origine synthétique ou naturel. Sous forme naturelle, il provient de la sève de 1 ' Hevea brasiliensis . II est très présent dans les objets de la vie quotidienne. A titre d'exemples d'objets en latex ou comprenant du latex qui sont donc de nature à provoquer des réactions allergiques on peut citer les gants de ménage, les pneus, les ballons, les tétines, les tubes de plongée, les palmes, les lunettes de natation, les bonnets de bains, les colles, les manches grips de raquette de tennis, les préservatifs, le matériel médical : bandages élastiques, seringues avec joints en caoutchouc, sondes, alèses, tubulures de perfusion, gouttières pour soins dentaires et gants d'examens ou de chirurgiens, etc.  Natural rubber or latex is an aqueous emulsion of spherical polyisoprene droplets wrapped in a layer of water soluble proteins. It can be of synthetic or natural origin. In natural form it comes from the sap of Hevea brasiliensis. He is very present in the objects of everyday life. Examples of objects made of latex or comprising latex which are therefore likely to cause allergic reactions include household gloves, tires, balloons, teats, diving tubes, fins, swimming goggles, swim caps, glues, grips tennis racket grips, condoms, medical equipment: elastic bandages, syringes with rubber gaskets, probes, pads, infusion sets, dental gutters and gloves exams or surgeons, etc.
La meilleure façon de prévenir les allergies de contact est d'éviter l'utilisation et/ou le contact avec des objets contenant les substances allergènes. Ainsi, pour prévenir les allergies au caoutchouc, il est recommandé de ne pas utiliser d'objets en caoutchouc.  The best way to prevent contact allergies is to avoid use and / or contact with objects containing allergens. Thus, to prevent rubber allergies, it is recommended not to use rubber objects.
Il existe des produits de substitution, notamment en polyuréthane, polyvinyle, nitrile, etc. permettant la substitution des objets ou dispositifs en caoutchouc, mais ceux-ci s'avèrent beaucoup plus onéreux et, pour ce qui est des doigtiers, gants, préservatifs, ils affectent la sensibilité au toucher. Il existe donc un réel besoin en un produit permettant de prévenir les allergies de contact et notamment les allergies au caoutchouc. De façon surprenante et inattendue les présents inventeurs ont trouvé qu'un agent chélatant amphotère particulier permettait de prévenir les allergies de contact . There are substitute products, especially polyurethane, polyvinyl, nitrile, etc. allowing the substitution of rubber objects or devices, but these are much more expensive and, as for finger cots, gloves, condoms, they affect the sensitivity to touch. There is therefore a real need for a product to prevent contact allergies and especially allergies to rubber. Surprisingly and unexpectedly the present inventors have found that a particular amphoteric chelating agent can prevent contact allergies.
Résumé de l'invention  Summary of the invention
D'une façon générale, la présente invention porte sur l'utilisation d'au moins un agent chélatant amphotère qui comprend un complexe à base d' aluminium et d' acide éthylène diamine tétraacétique ou son sel trisodique présentant la formule générale [Al ( Y) Bn] c' Dc avec B représentant OH~, B02 ~, H+, Y représentant un tétracarboxylate pouvant être protoné quatre fois pour former l'acide éthylène diamine tétraacétique, n représentant un nombre entier égal à 0, 1, 2 ou 3, D étant un contre-ion, de préférence Na+, c étant un nombre entier égal à 0, 1, 2 ou 3 et c' étant un nombre relatif ayant la même valeur absolue que c, pour prévenir les allergies de contact. In general, the present invention relates to the use of at least one amphoteric chelating agent which comprises a complex based on aluminum and ethylene diamine tetraacetic acid or its trisodium salt having the general formula [Al (Y ) B n] c 'c D with B representing OH ~, ~ B0 2, H +, Y representing a tetracarboxylate can be protonated four times to form the ethylene diamine tetraacetic acid, n is an integer equal to 0, 1, 2 or 3, D being a counter-ion, preferably Na + , c being an integer of 0, 1, 2 or 3 and c 'being a relative number having the same absolute value as c, to prevent allergies of contact.
Selon un autre aspect, la présente invention porte sur un dispositif comportant une partie en matériau allergène, notamment en latex, destinée à entrer en contact avec la peau ou les muqueuses, qui est recouverte par une couche contenant au moins un agent chélatant amphotère tel que mentionné ci-dessus.  According to another aspect, the present invention relates to a device comprising a portion of allergenic material, in particular latex, intended to come into contact with the skin or the mucous membranes, which is covered by a layer containing at least one amphoteric chelating agent such as mentioned above.
Selon encore un autre objet, la présente invention porte sur l'utilisation d'une composition comprenant au moins ledit agent chélatant amphotère mentionné précédemment et au moins un excipient, pour prévenir les allergies de contact.  According to yet another object, the present invention relates to the use of a composition comprising at least said amphoteric chelating agent mentioned above and at least one excipient, to prevent contact allergies.
Description Détaillée de l'Invention  Detailed Description of the Invention
La présente invention porte sur l'utilisation d'au moins un agent chélatant amphotère qui comprend un complexe à base d' aluminium et d' acide éthylène diamine tétraacétique ou son sel trisodique présentant la formule générale [Al ( Y) Bn] c' Dc avec B représentant OH", B02 ", H+, Y représentant un tétracarboxylate pouvant être protoné quatre fois pour former l'acide éthylène diamine tétraacétique, n représentant un nombre entier égal à 0, 1, 2 ou 3, D étant un contre-ion, de préférence Na+, c étant un nombre entier égal à 0, 1, 2 ou 3 et c' étant un nombre relatif ayant la même valeur absolue que c, pour prévenir les allergies de contact, en particulier, les allergies au caoutchouc . The present invention relates to the use of at least one amphoteric chelating agent which comprises a complex based on aluminum and ethylene diamine tetraacetic acid or its trisodium salt having the general formula [Al (Y) n B] c ' D c with B representing OH " , B0 2 " , H + , Y representing a tetracarboxylate which can be protonated four times to form ethylene diamine tetraacetic acid, n being an integer of 0, 1, 2 or 3, D being a counterion, preferably Na + , where c is an integer equal at 0, 1, 2 or 3 and c 'being a relative number having the same absolute value as c, to prevent contact allergies, in particular rubber allergies.
Dans la présente invention, par « allergies de contact » on entend toutes les allergies qui sont provoquées par le contact répété avec la peau et/ou les muqueuses de substances allergènes. A titre d' allergènes présents dans des objets ou dispositifs susceptibles d'entrer en contact avec la peau et/ou les muqueuses et qui provoquent des allergies de contact, on peut citer, les protéines du latex, des métaux lourds tels que Al, As, Cd, Cr, Hg, Ni, Pb, Sr et Te, le disulfure de tétraméthylthiuram, le 2-mercaptobenzothiazole, le carbamate de benzyle, le bisphénol, l'acrylate d'éthyle, l'araldite 506 epoxy Resin, le méthanal, les allergènes de type protéinique (tels que les profilines, les tropomyosines , les LTP (les protéines de transfert de lipides), les bet v 1-like protéines PR-10, les polcalcines, les bêta parvalbumines , les 2s albumines, les bêta expansines, les polygalacturonases, les Ag5 (antigènes 5) , les albumines, les caséines, les lipocalines, le groupe 5 des graminées, les Ils globulines, les 7s vicilin-like globulines, le groupe 4 des graminées, les papaïne-like protéases à cystéine, les phospholipases Al, les inhibiteurs de protéase à sérine, les hyaluronidases , les chitinases de classe 1, les thaumatin-like protéines, etc.) et leurs mélanges.  In the present invention, "contact allergies" means all allergies that are caused by repeated contact with the skin and / or mucous membranes of allergenic substances. As allergens present in objects or devices likely to come into contact with the skin and / or the mucous membranes and which cause contact allergies, mention may be made of latex proteins, heavy metals such as Al, As , Cd, Cr, Hg, Ni, Pb, Sr and Te, tetramethylthiuram disulfide, 2-mercaptobenzothiazole, benzyl carbamate, bisphenol, ethyl acrylate, araldite 506 epoxy Resin, methanal, Protein-type allergens (such as profilins, tropomyosins, LTPs (lipid transfer proteins), betv 1-like PR-10 proteins, polcalcines, beta parvalbumin, 2s albumin, beta expansins , polygalacturonases, Ag5 (antigens 5), albumins, caseins, lipocalins, group 5 grasses, They globulins, 7s vicilin-like globulins, group 4 grasses, papain-like cysteine proteases , phospholipases Al, protease inhibitors serine, hyaluronidases, class 1 chitinases, thaumatin-like proteins, etc.) and mixtures thereof.
L' invention est particulièrement appropriée pour la prévention des allergies au caoutchouc, et notamment au caoutchouc naturel. Dans la présente invention, par « allergies au caoutchouc » on entend les allergies provoquées par les protéines présentes dans le caoutchouc naturel dérivé de l'arbre Hevea brasiliensis, mais aussi par d'autres substances allergènes présentes dans le caoutchouc. A titre d'exemples de telles protéines allergènes, on peut citer l'hévéine, la prohévéine, la profiline, le facteur d'allongement du caoutchouc, l'endo- 1 , 3^-glucosidase, etc. D'autres exemples de substances allergènes non protéiniques présentes dans le caoutchouc sont les agents de vulcanisation (thiurames, dithiocarbamates , benzothiazoles , guanidines, et thiourées) , agents antioxydants ou antiozonants (dérivés de la PPD - phénylène paradiamine- et quinolines) , phénols (hydroquinones ) , phosphites... ou autres additifs tels que digluconate de chlorhexidine, sels de chlorure de diméthyl didécyl ammonium, isothiazolinones , formaldéhyde, métaux divers, etc.. The invention is particularly suitable for the prevention of allergies to rubber, and particularly to natural rubber. In the present invention, "rubber allergies" means allergies caused by the proteins present in the natural rubber derived from the Hevea brasiliensis tree, but also by other allergenic substances present in the rubber. Examples of such allergenic proteins include hevein, prohevein, profilin, elongation factor of rubber, endo-1,3-glucosidase, and the like. Other examples of non-protein allergenic substances present in the rubber are vulcanizing agents (thiurams, dithiocarbamates, benzothiazoles, guanidines, and thioureas), antioxidants or antiozonants (PPD derivatives - phenylene paradiamine and quinolines), phenols ( hydroquinones), phosphites ... or other additives such as chlorhexidine digluconate, dimethyl didecyl ammonium chloride salts, isothiazolinones, formaldehyde, various metals, etc.
De telles allergies de contact se manifestent par une dermite de contact, une urticaire de contact, un eczéma, des rhinites, des conjonctivites, de l'asthme, un choc anaphylactique .  Such contact allergies are manifest as contact dermatitis, contact urticaria, eczema, rhinitis, conjunctivitis, asthma, anaphylactic shock.
Dans le texte de la présente demande, par « allergies de contact » ou « allergies au caoutchouc » on désignera indifféremment l'allergie et ses manifestations.  In the text of the present application, by "contact allergies" or "allergies to rubber" will be indifferently denote the allergy and its manifestations.
L'agent chélatant amphotère de formule générale [Al (Y) Bn] c' Dc utilisé selon l'invention peut être formé de préférence par une combinaison quasi-stoechiométrique de l'ion aluminium Al3+, du ligand Y et d'un agent stabilisant choisi parmi OH~, B02~ ou H+ . En conséquence, son pH reste neutre, le plus petit de ses pK acides est dans la gamme de 6 à 10 alors que le plus grand de ses pK basiques est dans la gamme de 5 à 8, et le plus grand pK basique est inférieur au plus petit pK acide. Selon un mode de réalisation particulier, ledit complexe à base d'aluminium et d'Y est stabilisé par une base faible telle que les acides aminés choisis dans le groupe comprenant la glycine, l'histidine, l'arginine, la lysine, la phénylalanine, l'alanine, 1 ' isoleucine, la leucine, la méthionine, la proline, la valine, le tryptophane, la sérine, la glutamine, la cystine et leurs mélanges. La glycine est tout à fait appropriée. The amphoteric chelating agent of general formula [Al (Y) n B] c 'c D used according to the invention can be preferably formed by a substantially stoichiometric combination of aluminum ion Al 3+, Y ligand and a stabilizing agent chosen from OH ~ , B02 ~ or H + . As a result, its pH remains neutral, the smallest of its pK acids is in the range of 6 to 10 while the largest of its basic pK is in the range of 5 to 8, and the largest basic pK is less than smaller pK acid. According to a particular embodiment, said complex based on aluminum and Y is stabilized by a weak base such that the amino acids chosen from the group comprising glycine, histidine, arginine, lysine, phenylalanine alanine, isoleucine, leucine, methionine, proline, valine, tryptophan, serine, glutamine, cystine and mixtures thereof. Glycine is quite appropriate.
Selon l'invention, l'utilisation dudit agent chélatant amphotère est réalisée de telle sorte qu' il soit en contact avec la peau et/ou les muqueuses.  According to the invention, the use of said amphoteric chelating agent is carried out so that it is in contact with the skin and / or the mucous membranes.
L'efficacité d'utilisation de l'agent chélatant amphotère conforme à 1 ' invention a été testée par des analyses morphologiques basées sur la théorie suivante : Les cellules de Langerhans sont des cellules dendritiques que l'on retrouve dans l'épiderme et qui contiennent des granules de Birbeck. Ils existent normalement dans des ganglions lymphatiques et dans la peau au niveau du stratum spinosum de l'épiderme. Ces cellules spécialisées dans la captation des antigènes s'activent lorsque la peau est mise en contact avec un allergène. Cela présente un premier signe du début d'un processus de sensibilisation. Des méthodes d' immuno-marquage, notamment des récepteurs de surface CDla des cellules de Langerhans permettent d'en mesurer le nombre et d' observer leur migration de l'épiderme au derme. La composition préventive de l'invention est efficace si l'antigène est stoppé, c'est-à- dire non capté par les cellules de Langerhans épidermiques . Celles-ci ne vont donc pas migrer vers le derme. L'efficacité de la composition selon l'invention se mesure donc par le nombre de cellules de Langerhans non migrantes par centimètre d'épiderme. Il n'a pas été observé de migration sensible du nombre de ces cellules après mise en contact de la zone de peau couverte par la composition selon l'invention avec des agents allergènes et notamment avec les protéines allergènes du caoutchouc naturel telles que l'hévéine. The effectiveness of use of the amphoteric chelating agent according to the invention was tested by morphological analyzes based on the following theory: Langerhans cells are dendritic cells that are found in the epidermis and contain Birbeck granules. They normally exist in lymph nodes and in the skin in the stratum spinosum of the epidermis. These cells specialized in the capture of antigens are activated when the skin is put in contact with an allergen. This presents a first sign of the beginning of an awareness process. Immunolabelling methods, in particular CDla surface receptors of Langerhans cells make it possible to measure their number and to observe their migration from the epidermis to the dermis. The preventive composition of the invention is effective if the antigen is stopped, that is to say not captured by epidermal Langerhans cells. These will not migrate to the dermis. The effectiveness of the composition according to the invention is therefore measured by the number of non-migrating Langerhans cells per centimeter of epidermis. No significant migration of the number of these cells has been observed after contacting the skin zone covered by the composition. according to the invention with allergenic agents and in particular with the allergenic proteins of natural rubber such as hevein.
L' invention porte également sur un dispositif comportant une partie en matériau susceptible de contenir des allergènes destinée à entrer en contact avec la peau ou les muqueuses, qui est recouverte par une couche contenant au moins un agent chélatant amphotère qui comprend un complexe à base d' aluminium et d' acide éthylène diamine tétraacétique ou son sel trisodique présentant la formule générale [Al (Y) Bn] c' Dc avec B représentant OH", B02 ", H+, Y représentant un tétracarboxylate pouvant être protoné quatre fois pour former l'acide éthylène diamine tétraacétique, n représentant un nombre entier égal à 0, 1, 2 ou 3, D étant un contre-ion, de préférence Na+, c étant un nombre entier égal à 0, 1, 2 ou 3 et c' étant un nombre relatif ayant la même valeur absolue que c. The invention also relates to a device comprising a portion of material capable of containing allergens for contact with the skin or the mucous membranes, which is covered by a layer containing at least one amphoteric chelating agent which comprises a d-based complex. aluminum and ethylene diamine tetraacetic acid or its trisodium salt having the general formula [Al (Y) B n ] c D c with B representing OH " , B0 2 " , H + , Y being a tetracarboxylate which may be protonated four times to form ethylene diamine tetraacetic acid, where n is an integer of 0, 1, 2 or 3, D being a counterion, preferably Na + , where c is an integer of 0, 1, 2 or 3 and c 'being a relative number having the same absolute value as c.
L' invention est particulièrement adaptée aux dispositifs en caoutchouc ou comportant une partie en caoutchouc destinée à entrer en contact avec la peau et/ou les muqueuses.  The invention is particularly suitable for rubber devices or having a rubber part intended to come into contact with the skin and / or the mucous membranes.
Des exemples de dispositif selon l'invention sont les préservatifs, les gants, les doigtiers, les pansements et compresses, les dispositifs médicaux tels que sondes, tubulures, dispositifs de drainage, de perfusion, dispositifs médicaux utiles en urologie, dispositifs médicaux de l'abord respiratoire, etc.  Examples of devices according to the invention are condoms, gloves, finger cots, dressings and compresses, medical devices such as probes, tubing, drainage devices, infusion devices, medical devices useful in urology, medical devices of the invention. first respiratory, etc.
Selon un mode de réalisation particulier, au moins la partie du dispositif destiné à entrer en contact avec la peau et/ou les muqueuses, est recouverte d'un film comprenant ledit agent chélatant amphotère.  According to a particular embodiment, at least the part of the device intended to come into contact with the skin and / or the mucous membranes is covered with a film comprising said amphoteric chelating agent.
Ledit film est de préférence une préparation lubrifiante . Dans le cas des préservatifs, à la fois la surface externe et la surface interne peuvent être recouvertes d'une préparation lubrifiante comportant ledit agent chélatant amphotère de façon à prévenir les deux partenaires des allergies au latex. Said film is preferably a lubricating preparation. In the case of condoms, both the outer surface and the inner surface may be coated with a lubricating preparation comprising said amphoteric chelating agent so as to prevent both partners from experiencing latex allergies.
L'invention porte également sur l'utilisation d'une composition comprenant au moins un agent chélatant amphotère qui comprend un complexe à base d' aluminium et d'acide éthylène diamine tétraacétique ou son sel trisodique présentant la formule générale [Al (Y) Bn] c' Dc avec B représentant OH~, Βθ2 ~, H+, Y représentant un tétracarboxylate pouvant être protoné quatre fois pour former l'acide éthylène diamine tétraacétique, n représentant un nombre entier égal à 0, 1, 2 ou 3, D étant un contre-ion, de préférence Na+, c étant un nombre entier égal à 0, 1, 2 ou 3 et c' étant un nombre relatif ayant la même valeur absolue que c, et au moins un excipient, pour prévenir les allergies de contact et en particulier les allergies au caoutchouc. The invention also relates to the use of a composition comprising at least one amphoteric chelating agent which comprises a complex based on aluminum and ethylene diamine tetraacetic acid or its trisodium salt having the general formula [Al (Y) B n ] c ' D c with B representing OH ~ , Βθ 2 ~ , H + , Y representing a tetracarboxylate that can be protonated four times to form ethylene diamine tetraacetic acid, n representing an integer equal to 0, 1, 2 or 3, D being a counterion, preferably Na + , where c is an integer equal to 0, 1, 2 or 3 and c 'is a relative number having the same absolute value as c, and at least one excipient, for prevent contact allergies and especially rubber allergies.
La composition peut se présenter sous forme d'émulsion huile dans eau ou eau dans huile, sous forme de gel, en particulier de gel hydrophile ou gel de silicone.  The composition may be in the form of an oil-in-water or water-in-oil emulsion, in the form of a gel, in particular a hydrophilic gel or a silicone gel.
Ledit excipient présent dans la composition est un excipient de qualité pharmaceutique ou cosmétique.  Said excipient present in the composition is an excipient of pharmaceutical or cosmetic quality.
Des exemples d'excipients pouvant être présents dans la composition selon l'invention sont choisis parmi un agent gélifiant, des tensio-actifs , des cires ou huiles synthétiques ou naturelles, des agents hydratants et émollients, des agents anti-perspirants , des additifs améliorant la texture tels que des conditionneurs et des épaississants, des agents conservateurs, des colorants cosmétiques et alimentaires, des parfums, des arômes, des agents de régulation du pH et leurs mélanges. L'agent gélifiant ou épaississant peut être hydrophile ou peut être de type silicone. Les gélifiants hydrophiles peuvent être des gélifiants synthétiques, semi- synthétiques, ou naturels d'origine végétale, microbienne, animale ou minérale. Les gélifiants hydrophiles peuvent être par exemple des polymères et des copolymères d' acide acrylique, des polymères réticulés acrylate d'alkyle en Cio- 30/acrylate, polyacrylamide, poloxamer, dérivés cellulosiques (esters et éthers) , silices, fumée de silice, silicates , tels que silicates de magnésium-aluminium, chitine et ses dérivés, gélatine, xanthane, dextrane, gellane, carraghénanes , alginates, agar-agar, gélose, pectine, gomme d'acacia, gomme karaya, gomme adragante, gomme arabique, gomme de guar, gomme de caroube, amidon et ses dérivés, scléroglucane . La concentration en gélifiant ou épaississant est de 0,01 à 10% en poids, de préférence de 0,1 à 5% en poids, et plus préférentiellement encore de 0,5 à 3% en poids du poids total de la composition. Examples of excipients that may be present in the composition according to the invention are chosen from a gelling agent, surfactants, synthetic or natural waxes or oils, moisturizing and emollient agents, antiperspirants, additives improving texture such as conditioners and thickeners, preservatives, cosmetic and food colorants, fragrances, flavorings, pH control agents and mixtures thereof. The gelling agent or thickener may be hydrophilic or may be of the silicone type. The hydrophilic gelling agents may be synthetic, semi-synthetic or natural gelling agents of plant, microbial, animal or mineral origin. Hydrophilic gelling agents may be, for example, polymers and copolymers of acrylic acid, crosslinked polymers, C 10-30 alkyl acrylate, polyacrylamide, poloxamer, cellulose derivatives (esters and ethers), silicas, fumed silica, silicates , such as magnesium-aluminum silicates, chitin and its derivatives, gelatin, xanthan, dextran, gellan, carrageenans, alginates, agar-agar, agar, pectin, acacia gum, karaya gum, gum tragacanth, gum arabic, gum guar, locust bean gum, starch and its derivatives, scleroglucan. The concentration of gelling agent or thickener is from 0.01 to 10% by weight, preferably from 0.1 to 5% by weight, and more preferably from 0.5 to 3% by weight of the total weight of the composition.
L'agent gélifiant de type silicone est par exemple un polysiloxane-s-.  The silicone-type gelling agent is, for example, a polysiloxane-s-.
L'agent tensio-actif peut être hydrophobe avec un HLB de 3 à 10 ou hydrophile avec un HLB de 11 à 18. Cet agent tensio-actif est choisi dans le groupe comprenant des alcools gras éthoxylés, des acides et des esters gras (par exemple : cétéareth-12 , cétéareth-20 , cétéareth-33 , stéaryl cétyl alcool 20-éthoxylé, 2-polyhydroxystéarate polyglycéryl , glycéryl oléate, ester de sorbitan, ester de glycérol, PEG-mono/di-laurate, PEG-mono/di-stéarate, cétéaryl isononanoate, glycéryl stéarate, etc.), des carboxylates , des éthoxycarboxylates (par exemple : stéarate de sodium/potassium, acide alkyl-carboxylique, acide carboxylique éther alkyl-polyglycol , acide carboxylique éther polyglycol alkylphénol, alcool carboxyméthylé, éthoxycarboxylate, éthercarboxylate, etc.) et leurs mélanges. La quantité d'agent tensio-actif lorsqu'il est présent est de 0,1% à 10% en poids, de préférence de 0,5 à 5% en poids, et plus préférentiellement encore de 1 à 3% en poids du poids total de la composition. The surfactant may be hydrophobic with a HLB of 3 to 10 or hydrophilic with an HLB of 11 to 18. This surfactant is selected from the group consisting of ethoxylated fatty alcohols, fatty acids and esters (eg Example: ceteart-12, ceteart-20, ceteareth-33, stearyl cetyl alcohol 20-ethoxylated, 2-polyhydroxystearate polyglyceryl, glyceryl oleate, sorbitan ester, glycerol ester, PEG-mono / di-laurate, PEG-mono / di stearate, cetearyl isononanoate, glyceryl stearate, etc.), carboxylates, ethoxycarboxylates (for example: sodium / potassium stearate, alkyl carboxylic acid, carboxylic acid alkyl polyglycol ether, carboxylic acid ether polyglycol alkyl phenol, carboxymethyl alcohol, ethoxy carboxylate , ether carboxylate, etc.) and their mixtures. The amount of surfactant when present is from 0.1% to 10% by weight, preferably from 0.5 to 5% by weight, and more preferably from 1 to 3% by weight of the weight. total of the composition.
Les cires ou huiles synthétiques ou naturelles, choisies dans le groupe comprenant extrait de Carnauba, cire d'abeille, beurre de karité, triglycérides, stéarines, esters d'acides gras (par exemple : des alcools cétéaryliques , des éthers dicapryliques de cétyl palmitate, des carbonates dicapryliques, des isononanates cétéaryliques, des dimères distéaryl-tricarbonate, etc.), des huiles de silicone, des stéarates de zinc, des polyisobutènes , des octyldodécanols , des octyldécylxylosides , des alcools gras, des acides gras (par exemple : acide laurique, acide myristique, acide stéarique, etc.), des huiles végétales (par exemple: huile de tournesol, de jojoba, de cocos nucifera, de soja, d'amande, etc.), la vaseline, la lanoline et leurs mélanges .  Waxes or synthetic or natural oils, selected from the group comprising carnauba extract, beeswax, shea butter, triglycerides, stearines, fatty acid esters (for example: cetearyl alcohols, cetyl palmitate dicapryl ethers, dicaprylic carbonates, cetearyl isononanates, distearyl-tricarbonate dimers, etc.), silicone oils, zinc stearates, polyisobutenes, octyldodecanol, octyldecylxylosides, fatty alcohols, fatty acids (eg lauric acid) , myristic acid, stearic acid, etc.), vegetable oils (for example: sunflower, jojoba, coconut nucifera, soya, almond, etc.), petroleum jelly, lanolin, and mixtures thereof.
Les agents hydratants et émollients peuvent être choisis dans le groupe comprenant allantoïne, polyol (par exemple glycérol, polymères de glycérol, propylène glycol, sorbitol etc.), des extraits végétaux (par exemple des extraits d'aloe vera, de camomille, de concombre, de calendula, etc.), acide hyaluronique, acide pyrrolidone carboxylique, urée, chitosan, tocophérol, panthénol, butylène glycol, phospholipide, acide linoléique, acide γ- linoléique, alpha-bisabolol , et leurs mélanges.  The moisturizing and emollient agents may be chosen from the group comprising allantoin, polyol (for example glycerol, glycerol polymers, propylene glycol, sorbitol, etc.), plant extracts (for example extracts of aloe vera, chamomile, cucumber). calendula, etc.), hyaluronic acid, pyrrolidone carboxylic acid, urea, chitosan, tocopherol, panthenol, butylene glycol, phospholipid, linoleic acid, γ-linoleic acid, alpha-bisabolol, and mixtures thereof.
La concentration en agents hydratants et émollients est de 0,1 à 20% en poids, de préférence de 0,5 à 10% en poids, et plus préférentiellement encore de 1 à 5% en poids du poids total de la composition.  The concentration of moisturizing and emollient agents is from 0.1 to 20% by weight, preferably from 0.5 to 10% by weight, and more preferably from 1 to 5% by weight of the total weight of the composition.
Les agents anti-perspirants peuvent être choisis dans le groupe comprenant des sels d'aluminium, de préférence le sesqui-chlorhydrate d'aluminium, des sels d'aluminium et de zirconium, des complexes d' aluminium-zirconium octachlorohydrex glycine et leurs mélanges. La concentration en agent anti-perspirant est de 0,1 à 50% en poids, de préférence de 10 à 30% en poids, et plus préférentiellement encore de 15% en poids du poids total de la composition. The antiperspirants may be selected from the group consisting of aluminum salts, preferably the sesqui-aluminum hydrochloride, aluminum and zirconium salts, complexes of aluminum-zirconium octachlorohydrex glycine and mixtures thereof. The concentration of antiperspirant agent is 0.1 to 50% by weight, preferably 10 to 30% by weight, and more preferably 15% by weight of the total weight of the composition.
Les conditionneurs peuvent être choisis dans le groupe comprenant des polymères polycationiques désignés selon la nomenclature INCI polyquaterniums , des gommes quaternisées , des phospholipides quaternisés, et leurs mélanges. La concentration en conditionneur est de 0,1 à 20% en poids, de préférence de 0,5 à 10% en poids, et plus préférentiellement encore de 0,5 à 5% en poids du poids total de la composition.  Conditioners may be selected from the group consisting of polycationic polymers designated according to the INCI polyquaternium nomenclature, quaternized gums, quaternized phospholipids, and mixtures thereof. The conditioner concentration is from 0.1 to 20% by weight, preferably from 0.5 to 10% by weight, and more preferably from 0.5 to 5% by weight of the total weight of the composition.
Les agents conservateurs peuvent être choisis dans le groupe comprenant: ester para-hydroxybenzoique d'alkyle, isothiazolinone, imidazolidinyl urée, diazolidinyl urée, des bromo-nitro-propanediol, phénoxyéthanol , acide sorbique et ses sels, acide benzoique et ses sels, phénoxyéthanol, alcool benzylique, et leurs mélanges. La concentration est celle autorisée en cosmétique.  The preserving agents may be chosen from the group comprising: para-hydroxybenzoic alkyl ester, isothiazolinone, imidazolidinyl urea, diazolidinyl urea, bromo-nitro-propanediol, phenoxyethanol, sorbic acid and its salts, benzoic acid and its salts, phenoxyethanol, benzyl alcohol, and mixtures thereof. The concentration is the one authorized in cosmetics.
La concentration en colorants cosmétiques et alimentaires, parfums, arômes, agents de régulation du pH (par exemple, acide citrique, acide lactique, acide phosphorique, hydroxyde de sodium, potasse, amino-méthyl- propanol, triéthanolamine, etc.) et leurs mélanges, est de 0,1 à 50% en poids, de préférence de 10 à 30% en poids, et plus préférentiellement encore de 15% en poids du poids total de la composition.  The concentration of cosmetic and food colorants, perfumes, flavorings, pH-regulating agents (eg citric acid, lactic acid, phosphoric acid, sodium hydroxide, potassium hydroxide, amino-methylpropanol, triethanolamine, etc.) and mixtures thereof is 0.1 to 50% by weight, preferably 10 to 30% by weight, and more preferably still 15% by weight of the total weight of the composition.
De façon particulièrement intéressante, la composition est une préparation gélifiante, notamment une préparation lubrifiante. La préparation lubrifiante est une préparation hydrophile, une préparation de silicone ou une préparation lubrifiante à base de vaseline contenant ledit agent chélatant amphotère ou bien sous forme liquide ou bien sous forme solide. In a particularly interesting way, the composition is a gelling preparation, in particular a lubricating preparation. The lubricating preparation is a hydrophilic preparation, a silicone preparation or a vaseline lubricating preparation containing said amphoteric chelating agent or in liquid form or in solid form.
La quantité d'agent chélatant amphotère présente dans ladite composition est de 0,01 à 5%, de préférence de 0,02 à 4,4% et plus préférentiellement encore d'environ 2% en poids du poids total de la composition. Pour certaines applications, où les quantités d' allergènes sont très faibles, notamment lors de l'utilisation de latex déprotéiné, de très faibles quantités, même inférieures à 0,01% pourraient s'avérer suffisantes. Cependant, dans la généralité des cas une quantité inférieure à 0,01 % ne permet pas d'obtenir un effet préventif suffisant. Au-delà de 5% on n'observe pas d'amélioration sensible.  The amount of amphoteric chelating agent present in said composition is from 0.01 to 5%, preferably from 0.02 to 4.4% and more preferably from approximately 2% by weight of the total weight of the composition. For certain applications, where the amounts of allergens are very low, especially when using deproteinized latex, very small amounts, even less than 0.01%, could be sufficient. However, in most cases less than 0.01% does not provide a sufficient preventive effect. Beyond 5%, no noticeable improvement is observed.
Selon l'invention, la composition est utilisée en application topique, plus particulièrement cutanée. Elle peut également être utilisée par application sur la surface du dispositif destiné à entrer en contact avec la peau et/ou les muqueuses.  According to the invention, the composition is used for topical application, more particularly cutaneous. It can also be used by application on the surface of the device intended to come into contact with the skin and / or the mucous membranes.
Sans vouloir être liés par aucune théorie, les présents inventeurs sont d'avis que la composition selon l'invention permet de réaliser une barrière physique et chimique contre les allergènes. Plus particulièrement, après application et séchage, une couche barrière recouvre la peau assurant ainsi une barrière physique entre la peau et l'environnement extérieur, l'agent chélatant amphotère assurant quant à lui une barrière chimique en chélatant ou en réagissant chimiquement avec les allergènes entrant en contact avec cette composition.  Without wishing to be bound by any theory, the present inventors are of the opinion that the composition according to the invention makes it possible to provide a physical and chemical barrier against allergens. More particularly, after application and drying, a barrier layer covers the skin thus ensuring a physical barrier between the skin and the external environment, the amphoteric chelating agent ensuring a chemical barrier by chelating or chemically reacting with the incoming allergens. in contact with this composition.
Par cette double action, les allergènes sont empêchés d'entrer en contact avec la peau. Pour être efficace, la composition doit recouvrir en totalité la zone de peau et/ou de muqueuse susceptible d'entrer en contact avec le dispositif en latex, généralement les mains pour les gants en latex ou le sexe pour les préservatifs. Elle doit être appliquée sur toute la surface de contact. La quantité d'application de la composition selon l'invention est à raison d'environ 0,5 à 5 mg/cm2, de préférence d'environ 1 à 3 mg/cm2, et plus préférentiellement encore d'environ 1,5 mg/cm2. By this double action, allergens are prevented from coming into contact with the skin. To be effective, the composition must completely cover the area of skin and / or mucosa that may come into contact with the latex device, typically hands for latex gloves or sex for condoms. It must be applied over the entire contact area. The amount of application of the composition according to the invention is in the proportion of approximately 0.5 to 5 mg / cm 2 , preferably of approximately 1 to 3 mg / cm 2 , and still more preferably of approximately 1, 5 mg / cm 2.
EXEMPLES  EXAMPLES
Les exemples suivants décrivent certains modes de réalisation de la présente invention. Cependant, il est entendu que les exemples ne sont présentés qu'à titre illustratif seulement et ne limitent en aucun cas la portée de l'invention.  The following examples describe some embodiments of the present invention. However, it is understood that the examples are presented for illustrative purposes only and in no way limit the scope of the invention.
Dans les présents exemples, l'agent chélatant amphotère utilisé présente la formule suivante: [A1YB02]2- In the present examples, the amphoteric chelating agent used has the following formula: [A1YB02] 2-
Na 2 Na 2
EXEMPLE 1- COMPOSITION LUBRIFIANTE  EXAMPLE 1- LUBRICANT COMPOSITION
On prépare une composition lubrifiante contenant  A lubricating composition containing
Aloe vera 0,1 mg  Aloe vera 0.1 mg
Vaseline 100 mg  Vaseline 100 mg
Lanoline 35 mg  Lanolin 35 mg
Eau 15 mg  Water 15 mg
Agent chélatant amphotère 0,08 mg  Amphoteric chelating agent 0.08 mg
EXEMPLE 2 : Gel  EXAMPLE 2 Gel
* 49,5 mL eau  * 49.5 mL water
* 0,5 g gomme xanthane  * 0.5 g xanthan gum
* 0,2 mg d'agent chélatant amphotère  * 0.2 mg of amphoteric chelating agent
Le gel est préparé de la façon suivante : on verse l'eau dans un récipient. On agite tout en ajoutant la gomme et l'agent chélatant amphotère. On laisse reposer 10 min .  The gel is prepared as follows: the water is poured into a container. It is stirred while adding the gum and the amphoteric chelating agent. Let stand 10 min.
On mélange pour obtenir une texture lisse. EXEMPLE 3: EMULSION POUR USAGE EXTERNE Mix to obtain a smooth texture. EXAMPLE 3 EMULSION FOR EXTERNAL USE
On a préparé une émulsion comprenant les produits  An emulsion comprising the products was prepared
Cette émulsion huile dans l'eau présente les caractéristiques suivantes: This oil-in-water emulsion has the following characteristics:
viscosité Brookfield de 18000 cP, mesurée à une température de 20(+/-l)°C et avec une vitesse de mobile à 3/20 rpm,  Brookfield viscosity 18000 cP, measured at a temperature of 20 (+/- 1) ° C and with a mobile speed at 3/20 rpm,
pH de 6,45,  pH of 6.45,
Aucun déphasage ne s'est produit après stockage pendant 6 mois à la température ambiante.  No dephasing occurred after storage for 6 months at room temperature.
EXEMPLE 4 : Essai d'efficacité contre des allergènes EXAMPLE 4: Efficacy test against allergens
On prépare des explants de peau d'un diamètre moyen de 10 mm, provenant d'une abdoplastie d'une femme caucasienne de 49 ans. Ces explants sont maintenus vivants dans un milieu de culture BEM (BIO-EC explant Médium) à 37 °C en atmosphère humide et enrichie de 5% de CO2. Skin explants with an average diameter of 10 mm, originating from an abduction of a woman, are prepared. Caucasian 49 years old. These explants are kept alive in a BEM medium (BIO-EC Explant Medium) at 37 ° C in a humid atmosphere and enriched with 5% CO 2 .
On teste la composition de l'exemple 3 contre les allergènes suivants :  The composition of Example 3 is tested against the following allergens:
• métaux lourds (Al, As, Cd, Cr, Hg, Ni, Pb, Sr, Te) - ECP multi-element standard V Ref 0C467028 Merck;  Heavy metals (Al, As, Cd, Cr, Hg, Ni, Pb, Sr, Te) - ECP multi-element standard V Ref 0C467028 Merck;
Disulfure de tétraméthylthiuram - T2 420 ;  Tetramethylthiuram disulfide - T2 420;
2-Mercaptobenzothiazole - M3301;  2-Mercaptobenzothiazole - M3301;
Carbamate de Benzyle - B18200;  Benzyl carbamate - B18200;
Bisphénol - 13302;  Bisphenol - 13302;
Acrylate d'éthyle - W241806;  Ethyl acrylate - W241806;
Araldite 506 epoxy Resin - A3183;  Araldite 506 Epoxy Resin - A3183;
Hévéine - latex 4335932 ;  Hevein - latex 4335932;
Méthanal à 30% w/w - 116 99031.  Methanal at 30% w / w - 116 99031.
A To, on applique la composition de l'exemple 3 ci- dessus sur les explants de peau à un dosage de 3 mg/cm2. On laisse sécher pendant 15 mn . Ensuite, 25μ1 d'une solution de l'un des allergènes choisis dans la liste ci-dessus sont appliqués sur les explants de peau protégés par l'émulsion de l'exemple 3 (test) et sont également appliqués sur des explants de peau non-protégés (témoin) . On laisse reposer jusqu'à T4h, ce qui représente 4 heures d'exposition à l'allergène sans lavage ni friction abrasive. A TB is applied the composition of Example 3 above on the skin explants at a dosage of 3 mg / cm 2. It is allowed to dry for 15 minutes. Next, 25 μl of a solution of one of the allergens chosen from the above list are applied to the skin explants protected by the emulsion of Example 3 (test) and are also applied to non-skin explants. -protected (witness). It is left to rest until T 4h , which represents 4 hours of exposure to the allergen without washing or abrasive friction.
Parallèlement on prépare de la même façon des explants protégés par l'émulsion mais qui ne sont pas mis en contact avec une substance à tester (contrôle) .  At the same time emulsion-protected explants are prepared in the same way but are not brought into contact with a test substance (control).
L'efficacité de protection contre des allergènes est mesurée par l'analyse d' immuno-coloration de CDla. D'abord, les sections paraffinées de cellules Langerhans sont immuno-colorées avec des anticorps monoclonaux anti-CDla (ref. IM1590, clone O10, Beckman Coulter) pendant 1 heure à température ambiante. Cette immuno-coloration est renforcée par un système de streptavidine/biotine (Vector, PK-7200) et révélée en employant VIP (Vector, SK-4600) . Les nucléus sont contre-colorés par hémalum de Masson. Les cellules Langerhans sont comptées sur chaque section le long d'épiderme. La longueur de chaque section est mesurée par le logiciel Olympus Cell et le nombre moyen de cellules Langerhans par centimètre d'épiderme est calculé. The protective efficacy against allergens is measured by the immunostain analysis of CDla. First, the paraffin sections of Langerhans cells are immunostained with anti-CDla monoclonal antibodies (ref IM1590, clone O10, Beckman Coulter) for 1 hour at ambient temperature. This immunostaining is enhanced by a streptavidin / biotin system (Vector, PK-7200) and revealed using VIP (Vector, SK-4600). The nuclei are counterstained by Masson hemalum. Langerhans cells are counted on each section along the epidermis. The length of each section is measured by the Olympus Cell software and the average number of Langerhans cells per centimeter of epidermis is calculated.
L'efficacité de protection contre l'allergène est mesurée par le nombre de cellules Langerhans n'ayant pas migré .  The effectiveness of protection against the allergen is measured by the number of Langerhans cells that have not migrated.
Des échantillons sont prélevés pour tous les explants à T0 et à T4h et sont photographiés. Samples are taken for all explants at T 0 and T 4h and are photographed.
Les résultats sont présentés sur les figures 1 et 2. La figure 1 représente les explants à T0 et la figure 2 à T4h pour l'Hévéine. The results are shown in Figures 1 and 2. Figure 1 shows the explants at T 0 and Figure 2 at T 4h for hevein.
A To, le stratum corneum est fin, compact et modérément rempli de kératine en surface et remarquablement en bas. L'épiderme présente de 4 à 5 couches cellulaires avec une bonne morphologie et une spongiose légère sur le stratum germinativum. Le relief de jonction entre le derme et l'épiderme est marqué. Le derme papillaire présente des fibres assez épaisses construisant un réseau dense et il est bien cellularisé sans zone de lyse histologique apparente .  At To, the stratum corneum is thin, compact and moderately filled with keratin on the surface and remarkably below. The epidermis has 4-5 cell layers with good morphology and mild spongiosis on stratum germinativum. The junction relief between the dermis and the epidermis is marked. The papillary dermis has fairly thick fibers that build a dense network and is well cellularized without any apparent histological lysis zone.
L'épiderme des explants non-protégés présente 4-5 couches cellulaires avec des changements morphologiques remarquables. Ces changements sont caractérisés par une dénaturation cytoplasmique marquée (altération protéique) , une pycnose marquée et une spongiose marquée sur le stratum germinativum .  The epidermis of unprotected explants presents 4-5 cell layers with remarkable morphological changes. These changes are characterized by marked cytoplasmic denaturation (protein alteration), marked pycnosis and marked spongiosis on stratum germinativum.
En revanche, les explants protégés et "contrôle" ne montrent aucun changement histologique significatif. Des résultats analogues ont été obtenus avec chacun des autres allergènes testés. In contrast, protected explants and "control" show no significant histological changes. Similar results were obtained with each of the other allergens tested.
L'absence ou le bas niveau de changement cellulaire ainsi que la concentration faible d' interleukines ont démontré que la composition de l'exemple 3 protège la peau efficacement contre l'hévéine.  The absence or low level of cellular change as well as the low concentration of interleukins have demonstrated that the composition of Example 3 protects the skin effectively against hevein.
EXEMPLE 5 : composition pour préservatif  EXAMPLE 5 Composition for a condom
On prépare de la façon suivante 100 mL de gel  100 ml of gel are prepared as follows
lubrifiant comprenant : lubricant comprising:
- 99 mL d'eau purifiée  - 99 mL of purified water
0,5 g de scléroglucane  0.5 g of scleroglucan
0,4 mg d'agent chélatant amphotère  0.4 mg of amphoteric chelating agent
Ce gel est appliqué par enduction sur les faces internes et externes d'un préservatif en caoutchouc naturel en une quantité de 2,0 +/- 0,5 mg/cm2. This gel is applied by coating on the inner and outer sides of a natural rubber preservative in an amount of 2.0 +/- 0.5 mg / cm 2 .

Claims

REVENDICATIONS
1. Utilisation d'au moins un agent chélatant amphotère qui comprend un complexe à base d' aluminium et d'acide éthylène diamine tétraacétique ou son sel trisodique présentant la formule générale [Al (Y) Bn] c' Dc avec B représentant OH~, Βθ2 ~, H+, Y représentant un tétracarboxylate pouvant être protoné quatre fois pour former l'acide éthylène diamine tétraacétique, n représentant un nombre entier égal à 0, 1, 2 ou 3, D étant un contre-ion, de préférence Na+, c étant un nombre entier égal à 0, 1, 2 ou 3 et c' étant un nombre relatif ayant la même valeur absolue que c, pour prévenir les allergies de contact, en particulier les allergies au caoutchouc. 1. Use of at least one amphoteric chelating agent which comprises a complex of aluminum and ethylene diamine tetraacetic acid or its trisodium salt having the general formula [Al (Y) B n ] c D c with B representing OH ~ , Βθ 2 ~ , H + , Y representing a tetracarboxylate that can be protonated four times to form ethylene diamine tetraacetic acid, n represents an integer equal to 0, 1, 2 or 3, D being a counter-ion, preferably Na + , where c is an integer of 0, 1, 2 or 3 and c 'is a relative number having the same absolute value as c, to prevent contact allergies, especially rubber allergies.
2. Utilisation selon la revendication 1, caractérisée par le fait que l'allergie de contact est une allergie à une substance allergène, une dermite de contact, une urticaire de contact, eczéma, rhinites, conjonctivites, asthme, choc anaphylactique.  2. Use according to claim 1, characterized in that the contact allergy is an allergy to an allergenic substance, contact dermatitis, contact urticaria, eczema, rhinitis, conjunctivitis, asthma, anaphylactic shock.
3. Utilisation selon la revendication 1 ou 2, dans laquelle ledit agent chélatant est en contact avec la peau et/ou les muqueuses.  3. Use according to claim 1 or 2, wherein said chelating agent is in contact with the skin and / or the mucous membranes.
4. Utilisation selon l'une quelconque des  4. Use according to any one of
revendications 1 à 3, dans laquelle le composé amphotère est incorporé dans un dispositif et/ou dans une Claims 1 to 3, wherein the amphoteric compound is incorporated in a device and / or in a
composition . composition.
5. Dispositif comportant une partie en matériau contenant des agents allergènes qui est destinée à entrer en contact avec la peau ou les muqueuses, ladite partie étant recouverte par une couche contenant au moins un agent chélatant amphotère qui comprend un complexe à base d' aluminium et d' acide éthylène diamine tétraacétique ou son sel trisodique présentant la formule générale [Al (Y) Bn] c'Dc avec B représentant OH", B02 ", H+, Y représentant un tétracarboxylate pouvant être protoné quatre fois pour former l'acide éthylène diamine tétraacétique, n représentant un nombre entier égal à 0, 1, 2 ou 3, D étant un contre-ion, de préférence Na+, c étant un nombre entier égal à 0, 1, 2 ou 3 et c' étant un nombre relatif ayant la même valeur absolue que c. 5. A device comprising a portion of allergen-containing material which is intended to come into contact with the skin or the mucous membranes, said part being covered by a layer containing at least one amphoteric chelating agent which comprises an aluminum-based complex and of ethylene diamine tetraacetic acid or its trisodium salt having the general formula [Al (Y) B n ] c ' D c with B representing OH " , B0 2 " , H + , Y representing a tetracarboxylate which can be protonated four times to form ethylene diamine tetraacetic acid, n being an integer of 0, 1, 2 or 3, D being a counterion, preferably Na + , where c is an integer equal at 0, 1, 2 or 3 and c 'being a relative number having the same absolute value as c.
6. Dispositif selon la revendication 5, choisi parmi les préservatifs, les gants, les doigtiers, les pansements et compresses, les dispositifs médicaux tels que sondes, tubulures, dispositifs de drainage, de perfusion, dispositifs médicaux utiles en urologie, dispositifs médicaux de l'abord respiratoire.  6. Device according to claim 5, selected from condoms, gloves, finger cots, dressings and compresses, medical devices such as probes, tubing, drainage devices, infusion devices, medical devices useful in urology, medical devices of the world. first respiratory.
7. Dispositif selon la revendication 5 ou 6, dans lequel l'agent chélatant amphotère est présent dans un film déposé au moins sur la surface destinée à entrer en contact avec la peau et/ou les muqueuses. 7. Device according to claim 5 or 6, wherein the amphoteric chelating agent is present in a film deposited at least on the surface intended to come into contact with the skin and / or the mucous membranes.
8. Utilisation d'une composition comprenant au moins un agent chélatant amphotère qui comprend un complexe à base d' aluminium et d' acide éthylène diamine tétraacétique ou son sel trisodique présentant la formule générale [Al (Y) Bn] c' Dc avec B représentant OH", B02 ", H+, Y représentant un tétracarboxylate pouvant être protoné quatre fois pour former l'acide éthylène diamine tétraacétique, n représentant un nombre entier égal à 0, 1, 2 ou 3, D étant un contre-ion, de préférence Na+, c étant un nombre entier égal à 0, 1, 2 ou 3 et c' étant un nombre relatif ayant la même valeur absolue que c, et au moins un excipient, pour prévenir les allergies de contact, en particulier les allergies au caoutchouc. 8. Use of a composition comprising at least one amphoteric chelating agent which comprises a complex based on aluminum and ethylene diamine tetraacetic acid or its trisodium salt having the general formula [Al (Y) B n ] c ' D c with B representing OH " , B0 2 " , H + , Y representing a tetracarboxylate which can be protonated four times to form ethylene diamine tetraacetic acid, n being an integer of 0, 1, 2 or 3, D being a counter -ion, preferably Na + , c being an integer equal to 0, 1, 2 or 3 and c 'being a relative number having the same absolute value as c, and at least one excipient, to prevent contact allergies, especially allergies to rubber.
9. Utilisation selon la revendication 8, caractérisée par le fait que ledit excipient est choisi parmi un agent gélifiant, des tensio-actifs , des cires ou huiles synthétiques ou naturelles, des agents hydratants et émollients, des agents anti-perspirants , des additifs améliorant la texture tels que des conditionneurs , des agents conservateurs, des colorants cosmétiques et alimentaires, des parfums, des arômes, des agents de régulation du pH et leurs mélanges. 9. Use according to claim 8, characterized in that said excipient is selected from a gelling agent, surfactants, waxes or synthetic or natural oils, moisturizing agents and emollients, antiperspirants, texture enhancing additives such as conditioners, preservatives, cosmetic and food colorants, fragrances, flavorings, pH control agents and mixtures thereof.
10. Utilisation selon la revendication 9, caractérisée par le fait que l'agent gélifiant est choisi parmi les gélifiants hydrophiles tels que des polymères et des copolymères d'acide acrylique, des polymères réticulés acrylate d'alkyle en Cio-30/acrylate, polyacrylamide, poloxamer, dérivés cellulosiques (esters et éthers) , silices, silicates tels que silicates de magnésium- aluminium, chitine et ses dérivés, gélatine, xanthane, dextrane, gellane, carraghénanes , alginates, agar-agar, gélose, pectine, gomme d'acacia, gomme karaya, gomme adragante, gomme arabique, gomme de guar, gomme de caroube, amidon et ses dérivés, scléroglucane ; les agents gélifiants de type silicone, tels qu'un polysiloxane-s-, .  10. Use according to claim 9, characterized in that the gelling agent is selected from hydrophilic gelling agents such as polymers and copolymers of acrylic acid, crosslinked polymers C 10 -C 30 alkyl acrylate / acrylate, polyacrylamide , poloxamers, cellulose derivatives (esters and ethers), silicas, silicates such as magnesium aluminum silicates, chitin and its derivatives, gelatin, xanthan, dextran, gellan, carrageenans, alginates, agar-agar, agar, pectin, gum acacia, karaya gum, gum tragacanth, gum arabic, guar gum, locust bean gum, starch and its derivatives, scleroglucan; silicone-type gelling agents, such as a polysiloxane-s-,.
11. Utilisation selon l'une quelconque des revendications 7 à 9, caractérisée par le fait que la composition est une préparation lubrifiante choisie parmi une préparation lubrifiante hydrophile, une préparation lubrifiante de silicone ou une préparation lubrifiante à base de vaseline.  11. Use according to any one of claims 7 to 9, characterized in that the composition is a lubricant preparation selected from a hydrophilic lubricant preparation, a silicone lubricant preparation or a petroleum jelly preparation.
12. Utilisation ou dispositif selon l'une quelconque des revendications 1 à 11, caractérisé par le fait que l'agent chélatant amphotère est stabilisé par un acide aminé choisi dans le groupe comprenant la glycine, l'histidine, l'arginine, la lysine, la phénylalanine, l'alanine, 1 ' isoleucine, la leucine, la méthionine, la proline, la valine, le tryptophane, la sérine, la glutamine, la cystine et leurs mélanges.  12. Use or device according to any one of claims 1 to 11, characterized in that the amphoteric chelating agent is stabilized with an amino acid selected from the group comprising glycine, histidine, arginine, lysine phenylalanine, alanine, isoleucine, leucine, methionine, proline, valine, tryptophan, serine, glutamine, cystine and mixtures thereof.
EP13747452.4A 2012-07-18 2013-07-17 Use of an amphoteric chelating agent for preventing contact allergies Active EP2874604B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL13747452T PL2874604T3 (en) 2012-07-18 2013-07-17 Use of an amphoteric chelating agent for preventing contact allergies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1256939A FR2993466B1 (en) 2012-07-18 2012-07-18 USE OF A PROTECTIVE CREAM AGAINST THE EFFECTS OF AGGRESSIVE CHEMICAL AGENTS IN CONTACT WITH THE SKIN
PCT/FR2013/051718 WO2014013195A1 (en) 2012-07-18 2013-07-17 Use of an amphoteric chelating agent for preventing contact allergies

Publications (2)

Publication Number Publication Date
EP2874604A1 true EP2874604A1 (en) 2015-05-27
EP2874604B1 EP2874604B1 (en) 2018-02-14

Family

ID=47137836

Family Applications (2)

Application Number Title Priority Date Filing Date
EP13747451.6A Active EP2874661B1 (en) 2012-07-18 2013-07-17 Use of a cream that protects against the effects of aggressive chemical agents in contact with the skin
EP13747452.4A Active EP2874604B1 (en) 2012-07-18 2013-07-17 Use of an amphoteric chelating agent for preventing contact allergies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP13747451.6A Active EP2874661B1 (en) 2012-07-18 2013-07-17 Use of a cream that protects against the effects of aggressive chemical agents in contact with the skin

Country Status (18)

Country Link
US (3) US11197874B2 (en)
EP (2) EP2874661B1 (en)
CN (4) CN104470501A (en)
AU (2) AU2013291792B2 (en)
BR (2) BR112015001019B1 (en)
CA (2) CA2878882C (en)
DK (2) DK2874604T3 (en)
ES (2) ES2667709T3 (en)
FR (1) FR2993466B1 (en)
IN (1) IN2014DN10924A (en)
MX (2) MX359747B (en)
NO (1) NO2874604T3 (en)
NZ (2) NZ703409A (en)
PL (2) PL2874604T3 (en)
PT (1) PT2874604T (en)
SI (1) SI2874661T1 (en)
TR (1) TR201815143T4 (en)
WO (2) WO2014013194A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3093001B1 (en) * 2019-02-22 2022-06-10 Prevor Int COMPOSITION FOR REMOVING CHEMICAL RESIDUES AND USES THEREOF

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2604900B1 (en) * 1986-10-08 1989-01-13 Blomet Marie Claude PHYSIOLOGICAL SOLUTION FOR THE WASHING OF THE PARTS OF THE HUMAN BODY WHICH HAVE BEEN IN CONTACT WITH A FLUORHYDRIC ACID AND CONCENTRATED FOR ITS PREPARATION
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US5587400A (en) * 1993-04-19 1996-12-24 Marie-Claude Blomet epouse Meyer Physiological composition for the treatment of thermal or chemical burns
US5665804A (en) * 1996-02-05 1997-09-09 Dow Corning Corporation Silicone latex solvent thickening
SE9604610D0 (en) * 1996-12-16 1996-12-16 Noviscens Ab Medical composition
US6242042B1 (en) * 1998-09-14 2001-06-05 Lrc Products Ltd. Aqueous coating composition and method
US6582683B2 (en) * 2000-01-04 2003-06-24 Skinvisible Pharmaceuticals, Inc. Dermal barrier composition
FR2809959B1 (en) * 2000-06-07 2004-10-29 Marie Claude Meyer USE OF ALUMINUM COMPLEX AND LIGAND ETHYLENEDIAMINE-TETRAACETIC FOR THE PREVENTION AND / OR TREATMENT OF URTICARIA
GB0403702D0 (en) * 2004-02-19 2004-03-24 Boots Co Plc Skincare compositions
GB0324084D0 (en) * 2003-10-14 2003-11-19 Oxagen Ltd Compounds
JP2007508363A (en) * 2003-10-14 2007-04-05 オキサジェン リミテッド Compound having CRTH2 antagonist activity
US20090019224A1 (en) * 2005-02-02 2009-01-15 Pocrass Alan L Data Storage and Transfer Device and Method
WO2009092083A1 (en) * 2008-01-18 2009-07-23 Vystar Corporation Natural rubber latex having reduced allergenicity and method of making
WO2011041680A2 (en) * 2009-10-02 2011-04-07 The Brigham And Women's Hospital, Inc. Compositions and methods of prophylaxis for contact dermatitis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2014013195A1 *

Also Published As

Publication number Publication date
DK2874604T3 (en) 2018-05-22
CA2878882C (en) 2020-08-18
AU2013291793B2 (en) 2017-11-23
PT2874604T (en) 2018-05-11
CN108606964A (en) 2018-10-02
ES2667709T3 (en) 2018-05-14
CA2878882A1 (en) 2014-01-23
PL2874604T3 (en) 2018-07-31
WO2014013194A1 (en) 2014-01-23
TR201815143T4 (en) 2018-11-21
NO2874604T3 (en) 2018-07-14
US20150202217A1 (en) 2015-07-23
MX359747B (en) 2018-10-08
EP2874661A1 (en) 2015-05-27
NZ703409A (en) 2016-11-25
AU2013291793A1 (en) 2015-01-22
CA2878650C (en) 2020-07-21
IN2014DN10924A (en) 2015-09-18
BR112015001019B1 (en) 2022-07-19
CN104507501A (en) 2015-04-08
US10953024B2 (en) 2021-03-23
BR112015001018A2 (en) 2017-06-27
ES2690060T3 (en) 2018-11-19
PL2874661T3 (en) 2018-12-31
US20210275553A1 (en) 2021-09-09
EP2874604B1 (en) 2018-02-14
DK2874661T3 (en) 2018-11-05
BR112015001019A2 (en) 2017-06-27
FR2993466A1 (en) 2014-01-24
CA2878650A1 (en) 2014-01-23
FR2993466B1 (en) 2014-08-15
AU2013291792B2 (en) 2017-11-09
CN110179686A (en) 2019-08-30
MX2015000786A (en) 2015-09-16
US20150190357A1 (en) 2015-07-09
CN104470501A (en) 2015-03-25
SI2874661T1 (en) 2018-11-30
NZ703258A (en) 2016-11-25
WO2014013195A1 (en) 2014-01-23
MX356811B (en) 2018-06-13
AU2013291792A1 (en) 2015-01-22
EP2874661B1 (en) 2018-08-08
MX2015000785A (en) 2015-09-16
BR112015001018B1 (en) 2021-09-08
US11197874B2 (en) 2021-12-14

Similar Documents

Publication Publication Date Title
EP2874604B1 (en) Use of an amphoteric chelating agent for preventing contact allergies
US20200197379A1 (en) Composition for preventing or treating atopic dermatitis
EP3419588B1 (en) Composition for topical use based on a carnosine-magnesium complex
US20190365676A1 (en) Oral compositoins and methods of use
EP3056219B1 (en) Composition based on plants of the malvaceae family for mucosal delivery
EP3849671B1 (en) Use of reotier water to limit skin penetration of pollutants
TWI504347B (en) Anti-mosquito microcapsule composition, anti-mosquito microcapsule, anti-mosquito spray and anti-mosquito emulsion
FR3032619A1 (en) PLANT-BASED COMPOSITION OF MALVACEAE FAMILY FOR NASAL CAVITY ADMINISTRATION
FR3035330B1 (en) PLANT-BASED COMPOSITION OF THE MALVACEAE FAMILY FOR ADMINISTRATION IN OR AROUND NASAL CAVITY
WO2017144937A1 (en) Compositions for topical use based on a carnosine-magnesium complex
EP4025179A1 (en) Use of a composition containing an extract of tulipa gesneriana

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150210

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20151116

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20171116

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: FRENCH

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013033088

Country of ref document: DE

Ref country code: AT

Ref legal event code: REF

Ref document number: 969417

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180315

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2874604

Country of ref document: PT

Date of ref document: 20180511

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20180507

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2667709

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180514

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20180515

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20180214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 27149

Country of ref document: SK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180514

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20180401200

Country of ref document: GR

Effective date: 20181012

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013033088

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20181115

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20130717

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180614

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 969417

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180214

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20230619

Year of fee payment: 11

Ref country code: NO

Payment date: 20230623

Year of fee payment: 11

Ref country code: NL

Payment date: 20230622

Year of fee payment: 11

Ref country code: IE

Payment date: 20230619

Year of fee payment: 11

Ref country code: FR

Payment date: 20230517

Year of fee payment: 11

Ref country code: DK

Payment date: 20230626

Year of fee payment: 11

Ref country code: CZ

Payment date: 20230621

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20230619

Year of fee payment: 11

Ref country code: PL

Payment date: 20230621

Year of fee payment: 11

Ref country code: LU

Payment date: 20230622

Year of fee payment: 11

Ref country code: GR

Payment date: 20230621

Year of fee payment: 11

Ref country code: FI

Payment date: 20230626

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230704

Year of fee payment: 11

Ref country code: RO

Payment date: 20230703

Year of fee payment: 11

Ref country code: IT

Payment date: 20230710

Year of fee payment: 11

Ref country code: GB

Payment date: 20230725

Year of fee payment: 11

Ref country code: ES

Payment date: 20230807

Year of fee payment: 11

Ref country code: CH

Payment date: 20230802

Year of fee payment: 11

Ref country code: AT

Payment date: 20230621

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20230721

Year of fee payment: 11

Ref country code: DE

Payment date: 20230712

Year of fee payment: 11

Ref country code: BE

Payment date: 20230721

Year of fee payment: 11